All Access Articles |
- CG Oncology's Cretostimogene Achieves 41.8% 24-Month CR Rate | 2025-09-05 | PHARMACEUTICAL
- CG Oncology Reports Q2 Financials – Cash Position Declines | 2025-08-08 | PHARMACEUTICAL
- CG Oncology Reports 75.5% Complete Response Rate in Bladder Cancer Study | 2025-04-28 | UNITED STATES
- CG Oncology Reports $88M Net Loss in 2024 | 2025-03-28 | UNITED STATES